faCellitate GmbH, a pioneering company in advanced cell culture technologies, has proudly secured 1st place in the prestigious Technology Category at the 2024 Mannheim Business Start-Up Award (MEXI), sponsored by Roche Diagnostics. This accolade, awarded during the 20th anniversary of MEXI, recognizes faCellitate’s cutting-edge innovation, BIOFLOAT™, a revolutionary coating for 3D cell cultures transforming the […]
continue readingfaCellitate Announces Results of a Study on 3D Cell Culture:
Publication in Biotechnology Journal A broadly designed comparative study conducted by researchers from Karolinska Institute in Stockholm has shown that BIOFLOAT™ 3D Cell Culture Plates have performance characteristics superior over all other 3D Cell Culture Plates investigated. Mannheim (Germany) and Stockholm (Sweden), February 26, 2024: faCellitate GmbH has announced the results of a performance study […]
continue readingfaCellitate gibt die Ergebnisse einer Studie zur 3D-Zellkultur bekannt:
Veröffentlichung im Biotechnology Journal Eine breit angelegte Vergleichsstudie, die von Forschenden des Karolinska Instituts in Stockholm durchgeführt wurde, hat gezeigt, dass BIOFLOAT™ 3D-Zellkulturplatten Leistungsmerkmale besitzen, die den anderen untersuchten 3D-Zellkulturplatten überlegen sind. Mannheim (Deutschland) und Stockholm (Schweden), 26. Februar 2024: Die faCellitate GmbH hat die Ergebnisse einer Vergleichsstudie von 3D-Zellkulturplatten bekannt gegeben, die von […]
continue readingfaCellitate 2023: Cutting-edge Flat-Bottom microplates with Ultra-Low Adhesion Surface
faCellitate expands its product range with the launch of three new BIOFLOAT™ -coated flat-bottom microplates; a 96-well format, soon to be followed by 24- and 6-well plates. This innovative series is purposefully crafted as an addition to the BIOFLOAT 96-well and 384-well U-Bottom plates, catering to spheroid and organoid applications. The BIOFLOAT coated flat-bottom microplate […]
continue readingfaCellitate appoints Christoph Petry, Ph.D. to become Managing Director and CEO
faCellitate GmbH has appointed Dr. Christoph Petry, as Managing Director and CEO. Dr. Petry spun-out Sividon Diagnostics from Siemens Healthcare in 2010. Serving as Sividon’s CEO he oversaw the development of EndoPredict, a new standard to target breast cancer therapy and later successfully sold the company to Myriad Genetics. As a Managing Director he then […]
continue readingfaCellitate Starts Marketing New 384-well Spheroid Microplate
faCellitate expands its BIOFLOAT™ coated microplate portfolio by a 384 well format specifically designed for spheroid culture The exceptional performance of the BIOFLOAT™ coating combined with the high density 384-format makes the new product solution particularly valuable for high-throughput spheroid screening Accelerated assays due to spheroid culture without centrifugation and unique spheroid quality – experts […]
continue readingfaCellitate, ein BASF-Spin-off, schließt eine 3,7 Mio. € Seed-Runde unter Führung von SARSTEDT und dem HTGF ab
Erfolgreiches Closing der Seedrunde über 3,7 Millionen Euro unter Beteiligung von SARSTEDT, High-Tech Gründerfonds (HTGF), R3 Consulting, ARVE Capital, ROI Verwaltungsgesellschaft und Chemovator. faCellitate hat eine intelligente und extrem niedrig anhaftende Plattform für Polymeroberflächenbeschichtungen entwickelt. Das erste auf dem Markt eingeführte Produkt zielt auf die 3D-Zellkultur ab und ermöglicht eine einfache, zuverlässige und reproduzierbare 3D-Zellkultivierung, […]
continue readingfaCellitate, a BASF spin-off, closes a €3.7m seed round led by SARSTEDT and HTGF
Closing of seed round completed raising €3.7 million from SARSTEDT, High-Tech Gründerfonds (HTGF), R3 Consulting, ARVE Capital, ROI Verwaltungsgesellschaft and Chemovator. faCellitate has developed an intelligent and ultra-low attachment polymer surface coating platform. The first launched product thereof is targeting 3D cell culture, enabling simple, reliable, and reproducible 3D cell cultivation that challenges the industry’s […]
continue reading